AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30897865 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS nursing group
Number of subjects: 100
Study 27052428 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuvirtide (320 mg) and Lopinavir/Ritonavir (400/100 mg)
Number of subjects: 10
Study 27052428 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/Ritonavir (400/100 mg)
Number of subjects: 10
Study 27052428 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir
Number of subjects: 10
Study 26293147 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic and resistance exercise (n = 44)
Number of subjects: 94
Study 26293147 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 45)
Number of subjects: 94
Study 23855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Midazolam 0.5 mg/kg
Number of subjects: 40
Study 23855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Diazepam 0.5 mg/kg
Number of subjects: 40
Study 23855176 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Midazolam 0.06 mg/kg
Number of subjects: 40
Study 23855176 — intervention group
Group type: COMPARATOR
Intervention: Oral Placebo
Number of subjects: 40
Study 21394570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy follow-up (PF)
Number of subjects: 161
Study 21394570 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 161
Study 19643769 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective CPAP
Number of subjects: 56
Study 19643769 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 56
Study 17950834 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 1306
Study 15889589 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential static wrist orthoses (custom-fit)
Number of subjects: 30
Study 15889589 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential static wrist orthoses (off-the-shelf)
Number of subjects: 30
Study 15889589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wrist orthoses)
Number of subjects: 30
Study 12520634 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1,000 mg/m2 twice daily on days 1 to 14) plus IV irinotecan (250 mg/m2 on day 1 every 21 days)
Number of subjects: 700
Study 12520634 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine/irinotecan
Number of subjects: 700
Study 12520634 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/leucovorin
Number of subjects: 700
Study 9695724 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 31
Study 9695724 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 31
Study 7521118 — intervention group
Group type: COMPARATOR
Intervention: Chlormadinone acetate alone (group A)
Number of subjects: 70
Study 7521118 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate in combination with UFT (group B)
Number of subjects: 70
Study 2683878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 36
Study 2683878 — intervention group
Group type: EXPERIMENTAL
Intervention: Aziatropine
Number of subjects: 36
Study 4524016 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride application once a year
Number of subjects: 487
Study 4524016 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluoride application twice a year with 6 month interval
Number of subjects: 487
Study 4524016 — intervention group
Group type: COMPARATOR
Intervention: No topical fluoride application (control group)
Number of subjects: 487
Study 30388270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 68
Study 30388270 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 68
Study 28034081 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 400
Study 28034081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 25110841 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI risk‐reduction intervention
Number of subjects: 9
Study 25110841 — intervention group
Group type: COMPARATOR
Intervention: Attention-control intervention
Number of subjects: 9
Study 23594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) administered at a dosing scheme of 50 U kg(‐1) up to 84 kg, with a fixed dose of 4200 U above 84 kg.
Number of subjects: 133
Study 23594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) in symptomatic HAE patients.
Number of subjects: 133
Study 23594263 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 inhibitor (rhC1INH) in healthy volunteers.
Number of subjects: 133
Study 21615875 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose CTPI (19.62 mSv)
Number of subjects: 47
Study 21615875 — intervention group
Group type: COMPARATOR
Intervention: Median dose CTPI (12.61 mSv)
Number of subjects: 47
Study 21615875 — intervention group
Group type: COMPARATOR
Intervention: Low-dose CTPI (7.01 mSv)
Number of subjects: 47
Study 21615875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CTPI in patients with HCC
Number of subjects: 47
Study 19492636 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam imaging (CB)
Number of subjects: 27
Study 19492636 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopantomography (OPG)
Number of subjects: 27
Study 19492636 — intervention group
Group type: COMPARATOR
Intervention: Computerized Tomography (CT)
Number of subjects: 27
Study 17109592 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily NPH/regular insulin
Number of subjects: 94
Study 17109592 — intervention group
Group type: COMPARATOR
Intervention: Once-daily glargine insulin
Number of subjects: 94
Study 15379419 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants of mothers with gestational diabetes mellitus (IGDM)
Number of subjects: 37
Study 15379419 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 15379419 — intervention group
Group type: EXPERIMENTAL
Intervention: All study participants
Number of subjects: 37
Study 15379419 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with postnatal hypoglycemia
Number of subjects: 37
Study 15379419 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HbA1c during pregnancy
Number of subjects: 37
Study 11483801 — intervention group
Group type: EXPERIMENTAL
Intervention: AA+DHA from fish/fungal oil (N = 140)
Number of subjects: 470
Study 11483801 — intervention group
Group type: EXPERIMENTAL
Intervention: AA+DHA from egg‐TG/fish oil (N = 143)
Number of subjects: 470
Study 11483801 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 144)
Number of subjects: 470
Study 9462387 — intervention group
Group type: COMPARATOR
Intervention: MMP-9 level at 24 hours after operation
Number of subjects: 15
Study 9462387 — intervention group
Group type: COMPARATOR
Intervention: MMP-2 and MMP-9 levels in wound fluid
Number of subjects: 15
Study 9462387 — intervention group
Group type: COMPARATOR
Intervention: MMP-9 level at 24-48 hours after operation
Number of subjects: 15
Study 7520297 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution with low molecular weight hydroxyethyl starch (HS-HES)
Number of subjects: 45
Study 7520297 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight hydroxyethyl starch solution (LMW-HES)
Number of subjects: 45
Study 7520297 — intervention group
Group type: COMPARATOR
Intervention: Control group (no volume loading)
Number of subjects: 45
Study 2837106 — intervention group
Group type: EXPERIMENTAL
Intervention: terbutaline (7 micrograms/kg, subcutaneous injection)
Number of subjects: 18
Study 2837106 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 29297230 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacc-4x
Number of subjects: 93
Study 29297230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 27466000 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses (CMFOs)
Number of subjects: 41
Study 27466000 — intervention group
Group type: COMPARATOR
Intervention: Simple insoles (SIs)
Number of subjects: 41
Study 27466000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness comparison
Number of subjects: 41
Study 26550795 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions
Number of subjects: 23711
Study 26550795 — intervention group
Group type: COMPARATOR
Intervention: Interrupted chest compressions
Number of subjects: 23711
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: loose snus (27.1 mg nicotine)
Number of subjects: 20
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: pouched snus (14.7 mg nicotine)
Number of subjects: 20
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: loose snus (10.8 mg nicotine)
Number of subjects: 20
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: nicotine gum (4.2 mg nicotine)
Number of subjects: 20
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: cigarette
Number of subjects: 20
Study 22585541 — intervention group
Group type: EXPERIMENTAL
Intervention: pouched snus (1 g portion, ~11 mg nicotine)
Number of subjects: 20
Study 21577030 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week twice weekly exercise group program (gymnastics, movement games, relaxation, walking, jogging)
Number of subjects: 58
Study 21577030 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (control)
Number of subjects: 58
Study 18283240 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased serum concentrations of IgM and IgA against LPS from gram-negative enterobacteria in MDD patients
Number of subjects: 0
Study 18283240 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic performance of IgM and IgA levels
Number of subjects: 0
Study 18283240 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms associated with increased IgM and IgA levels
Number of subjects: 0
Study 18283240 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal mucosal dysfunction (leaky gut)
Number of subjects: 0
Study 16765863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway for treating pneumonia
Number of subjects: 6
Study 16765863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing administrators' perspective
Number of subjects: 6
Study 12668300 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 36
Study 10505800 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic bone mineral density (BMD) measures
Number of subjects: 292
Study 10505800 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized osteopenia
Number of subjects: 292
Study 8904260 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diazepam and propofol
Number of subjects: 150
Study 8904260 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam alone
Number of subjects: 150
Study 8904260 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol alone
Number of subjects: 150
Study 2276106 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly telephone call intervention in addition to usual care
Number of subjects: 55
Study 2276106 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 533286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined topical applications of a steroid and nonsteroid anti-inflammatory agent
Number of subjects: 0
Study 533286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroid anti-inflammatory agent
Number of subjects: 0
Study 533286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of steroid and nonsteroid agents
Number of subjects: 0
Study 533286 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid or nonsteroid agent alone
Number of subjects: 0
Study 533286 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of agents
Number of subjects: 0
Study 30022296 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 116
Study 30022296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 28877245 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging unpaid informal providers (IPs) in the Early arm
Number of subjects: 410278
Study 28877245 — intervention group
Group type: COMPARATOR
Intervention: Delayed arm (control)
Number of subjects: 410278
Study 25766689 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care (PC)
Number of subjects: 210
Study 25766689 — intervention group
Group type: COMPARATOR
Intervention: Sleep Unit (SU)
Number of subjects: 210
Study 25139550 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine/cisplatin (GC)
Number of subjects: 119
Study 25139550 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine/cisplatin/iniparib (GCI)
Number of subjects: 119
Study 22459230 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral hydration
Number of subjects: 85
Study 19088698 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine infusion (0.25 microg kg(‐1) hr(‐1))
Number of subjects: 90
Study 19088698 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam infusion (25 microg kg(‐1) hr(‐1))
Number of subjects: 90
Study 19088698 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 90
Study 17604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive treatment strategy
Number of subjects: 1163
Study 17604045 — intervention group
Group type: COMPARATOR
Intervention: Selective invasive (SI) treatment strategy
Number of subjects: 1163
Study 17604045 — intervention group
Group type: COMPARATOR
Intervention: Patients with SigmaST-segment deviation of at least 1 mm randomized to SI who did not undergo angiography
Number of subjects: 1163
Study 17604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SigmaST-segment deviation of at least 1 mm who underwent angiography before discharge
Number of subjects: 1163
Study 17604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ST-segment deviation
Number of subjects: 1163
Study 15998467 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EDBP)
Number of subjects: 40
Study 15998467 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (24 hours bed rest and ample fluid intake)
Number of subjects: 40
Study 11929349 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (600 mg/day)
Number of subjects: 0
Study 11929349 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 0
Study 9468157 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline and rifampin-coated catheters
Number of subjects: 158
Study 9468157 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheters (control)
Number of subjects: 158
Study 7630912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral care regime using saline rinses
Number of subjects: 0
Study 7630912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral assessment guide and protocol
Number of subjects: 0
Study 2905069 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg daily)
Number of subjects: 6
Study 2905069 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (10 mg for one night)
Number of subjects: 6
Study 2905069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2905069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for one night)
Number of subjects: 6
Study 28278611 — intervention group
Group type: EXPERIMENTAL
Intervention: Allow Natural Death (AND)
Number of subjects: 234
Study 28278611 — intervention group
Group type: COMPARATOR
Intervention: Do Not Resuscitate (DNR)
Number of subjects: 234
Study 28247979 — intervention group
Group type: COMPARATOR
Intervention: High-intensity aerobic training (HAT, 75% HRR)
Number of subjects: 34
Study 28247979 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity aerobic training (MAT, 60% HRR)
Number of subjects: 34
Study 28247979 — intervention group
Group type: EXPERIMENTAL
Intervention: Control group (CG)
Number of subjects: 34
Study 26243144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 87
Study 26243144 — intervention group
Group type: COMPARATOR
Intervention: Generic feedback
Number of subjects: 87
Study 26243144 — intervention group
Group type: EXPERIMENTAL
Intervention: Both tailored and generic feedback
Number of subjects: 87
Study 23714894 — intervention group
Group type: EXPERIMENTAL
Intervention: Poly(lactic-co-glycolic) acid/hydroxyapatite (PLGA/HA)
Number of subjects: 0
Study 23714894 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone (DBB)
Number of subjects: 0
Study 20386078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 2 weeks
Number of subjects: 19
Study 20386078 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 19
Study 18377693 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-enzyme Q10 (100 mg), Riboflavin (10 mg), Niacin (50 mg) along with Tamoxifen (10 mg twice per day)
Number of subjects: 84
Study 18377693 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 84
Study 18377693 — intervention group
Group type: COMPARATOR
Intervention: Untreated breast cancer patients
Number of subjects: 84
Study 20356911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous n-3 polyunsaturated fatty acids (PUFA) infusion (3.9 g)
Number of subjects: 8
Study 20356911 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 8
Study 20356911 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous n-3 PUFA infusion
Number of subjects: 8
Study 15598604 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress situation
Number of subjects: 153
Study 15598604 — intervention group
Group type: COMPARATOR
Intervention: No-stress situation
Number of subjects: 153
Study 11403364 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5/10 mg) +/‐ Perindopril (4/8 mg)
Number of subjects: 19342
Study 11403364 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50/100 mg) +/‐ Bendroflumethiazide (1.25/2.5 mg) + K+
Number of subjects: 19342
Study 11403364 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 19342
Study 11403364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19342
Study 9755995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg at bedtime (maintenance group)
Number of subjects: 84
Study 9755995 — intervention group
Group type: COMPARATOR
Intervention: No active therapy (antibiotic group)
Number of subjects: 84
Study 9755995 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg at bedtime (intent to treat analysis)
Number of subjects: 84
Study 9755995 — intervention group
Group type: COMPARATOR
Intervention: No active therapy (intent to treat analysis)
Number of subjects: 84
Study 8167164 — intervention group
Group type: EXPERIMENTAL
Intervention: Group relaxation training and thermal biofeedback
Number of subjects: 101
Study 8167164 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study 3283093 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin sachets 3g twice daily for three days
Number of subjects: 41
Study 3283093 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin capsules 500 mg three times daily for seven days
Number of subjects: 41
Study 3283093 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course high dose therapy
Number of subjects: 41
Study 3283093 — intervention group
Group type: COMPARATOR
Intervention: Conventional course amoxycillin
Number of subjects: 41
Study 31296601 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC+LP
Number of subjects: 100
Study 31296601 — intervention group
Group type: COMPARATOR
Intervention: SMC
Number of subjects: 100
Study 29696564 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic acid) administered at a dose of two capsules (500 mg) per day orally for 12 weeks
Number of subjects: 0
Study 29696564 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 29696564 — intervention group
Group type: EXPERIMENTAL
Intervention: M2000 (β-D-mannuronic acid)
Number of subjects: 0
Study 27177524 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese women after protocol implementation
Number of subjects: 5000
Study 27177524 — intervention group
Group type: COMPARATOR
Intervention: Obese women before protocol implementation
Number of subjects: 5000
Study 24337884 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diet group (clear liquid diet on day 0, soft diet and general diet on day 1)
Number of subjects: 130
Study 24337884 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diet group
Number of subjects: 130
Study 24337884 — intervention group
Group type: COMPARATOR
Intervention: Control group (fasted for 2 days)
Number of subjects: 130
Study 23200102 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 0.0025, 0.025, 0.15, 0.6, 2, or 6 mg/kg
Number of subjects: 33
Study 23200102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inactive vehicle)
Number of subjects: 33
Study 23200102 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1 2 and 6 mg/kg
Number of subjects: 33
Study 23200102 — intervention group
Group type: EXPERIMENTAL
Intervention: GNbAC1
Number of subjects: 33
Study 19130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in the household of origin continuously (IN)
Number of subjects: 181
Study 19130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaving and never returning (OUT)
Number of subjects: 181
Study 19130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple moves in and out of the household (IN/OUT)
Number of subjects: 181
Study 19130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adolescent maternal age, less supportive adolescent mother-grandmother relations, and high household density
Number of subjects: 181
Study 19130358 — intervention group
Group type: EXPERIMENTAL
Intervention: IN/OUT group
Number of subjects: 181
Study 17957907 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (0.5 gm capsule, twice daily)
Number of subjects: 170
Study 17957907 — intervention group
Group type: COMPARATOR
Intervention: Dimenhydrinate (50 mg capsule, twice daily)
Number of subjects: 170